Julie Skulikidis
Family · Commack, NYNPI 1225664204
Payments from drug & device makers
Across 504 payments — averaging $21.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$1K
- Xeris Pharmaceuticals, Inc.$1K
- AbbVie$610
- Dexcom, Inc.$598
- plus $5K from 35 others
What the payments were for
- Food & beverage$10,72299%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RECORLEV$118
How this compares
$10,782 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 110 | $155,564 |
| JardianceEmpagliflozin | 26 | $42,947 |
| OzempicSemaglutide | 36 | $42,594 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $18,601 |
| TradjentaLinagliptin | 16 | $17,456 |
| JanuviaSitagliptin Phosphate | 12 | $17,236 |
| TrulicityDulaglutide | 11 | $11,514 |
| XyostedTestosterone Enanthate | 13 | $8,748 |
| SynthroidLevothyroxine Sodium | 55 | $3,970 |
| Humalog Kwikpen U-100Insulin Lispro | 14 | $3,248 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,607 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 22 | $1,800 |
| Levothyroxine Sodium | 97 | $1,698 |
| Metformin Hcl | 54 | $660 |
| Metformin Hcl ErMetformin Hcl | 46 | $616 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,227 | $167,079121 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,164 | $60,40342 claims |
| Novo NordiskOzempic | $1,315 | $42,59436 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $422 | $18,60118 claims |
| MerckJanuvia | $158 | $17,23612 claims |
| Antares Pharma, Inc.Xyosted | $14 | $8,74813 claims |
| AbbVieSynthroid | $610 | $3,97055 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $325 | $1,69897 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Commack
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.